Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Predictors of mortality in Staphylococcus aureus bacteremia
SJ Van Hal, SO Jensen, VL Vaska… - Clinical microbiology …, 2012 - Am Soc Microbiol
Staphylococcus aureus bacteremia (SAB) is an important infection with an incidence rate
ranging from 20 to 50 cases/100,000 population per year. Between 10% and 30% of these …
ranging from 20 to 50 cases/100,000 population per year. Between 10% and 30% of these …
Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains …
The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and
heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past …
heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past …
Antimicrobial heteroresistance: an emerging field in need of clarity
SUMMARY “Heteroresistance” describes a phenomenon where subpopulations of
seemingly isogenic bacteria exhibit a range of susceptibilities to a particular antibiotic …
seemingly isogenic bacteria exhibit a range of susceptibilities to a particular antibiotic …
Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis
S Svetitsky, L Leibovici, M Paul - Antimicrobial agents and …, 2009 - Am Soc Microbiol
Vancomycin and teicoplanin are the glycopeptides currently in use for the treatment of
infections caused by invasive beta-lactam-resistant gram-positive organisms. We conducted …
infections caused by invasive beta-lactam-resistant gram-positive organisms. We conducted …
Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic …
Importance Staphylococcus aureusbacteremia (SAB) is a worldwide problem. It is unclear
whether higher-vancomycin minimum inhibitory concentration (MIC) is associated with …
whether higher-vancomycin minimum inhibitory concentration (MIC) is associated with …
Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)
PC Appelbaum - International journal of antimicrobial agents, 2007 - Elsevier
Vancomycin and other glycopeptide antibiotics are the current mainstay of therapy for
infections caused by methicillin-resistant Staphylococcus aureus (MRSA). However, the high …
infections caused by methicillin-resistant Staphylococcus aureus (MRSA). However, the high …
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus …
S Zhang, X Sun, W Chang, Y Dai, X Ma - PloS one, 2015 - journals.plos.org
Background Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous
VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an …
VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an …
Comparison of Detection Methods for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus, with the Population Analysis Profile Method as the …
SW Satola, MM Farley, KF Anderson… - Journal of clinical …, 2011 - Am Soc Microbiol
Staphylococcus aureus clinical isolates with vancomycin MICs of 2 μg/ml have been
associated with vancomycin therapeutic failure and the heteroresistant vancomycin …
associated with vancomycin therapeutic failure and the heteroresistant vancomycin …
Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
SJ van Hal, DL Paterson - Antimicrobial agents and …, 2011 - Am Soc Microbiol
The prevalence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA)
is 1.3% in published studies. Clinical associations include high-inoculum infections and …
is 1.3% in published studies. Clinical associations include high-inoculum infections and …